This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Video decision support tool for advance care planning in dementia: randomised controlled trial
Volandes, Angelo E.,
Paasche-Orlow, Michael K.,
Barry, Michael J.,
Gillick, Muriel R.,
Minaker, Kenneth L.,
Chang, Yuchiao,
Cook, E. Francis,
Abbo, Elmer D.,
El-Jawahri, Areej,
Mitchell, Susan L.
Objective: To evaluate the effect of a video decision support tool on the preferences for future medical care in older people if they develop advanced dementia, and the stability of those preferences after six weeks.; Design: Randomised controlled trial conducted between 1 September 2007 and 30 May 2008. Setting Four primary care clinics (two geriatric […]
Improvement of spontaneous speech in early stage Alzheimer’s with rivastigmine
Visch Brink, E. G.,
Van Rhee Temme, W.,
Rietveld, T.,
Krulder, J. W. M.,
Van Harskamp, F.,
Van der Cammen, T. J. M.
Objectives: Placebo-controlled trials have shown that rivastigmine can delay cognitive deterioration in patients with mild to moderate Alzheimer’s disease (AD). Benefits on cognitive functioning, as measured with the ADAS-Cog, occur on a daily dose of 6-12 mg when used for at least 6 months. The effect of rivastigmine on the adequacy of spontaneous speech is […]
Long-term effects of rivastigmine capsules in patients with traumatic brain injury
Silver, Jonathan M.,
Koumaras, Barbara,
Meng, Xiangyi,
Potkin, Steven G.,
Reyes, Patricio F.,
Harvey, Philip D.,
Katz, Douglas I.,
Gunay, Ibrahim,
Arciniegas, David B.
Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]
Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia
Schmidt, Reinhold,
Alf, Claude,
Bancher, Christian,
Benke, Thomas,
Berek, Klaus,
Dal-Bianco, Peter,
Führwürth, Gerhard,
Imarhiagbe, Douglas,
Jagsch, Christian,
Lechner, Anita,
Rainer, Michael,
Reisecker, Franz,
Rotaru, Juliana,
Uranüs, Margarete,
Walter, Andreas,
Winkler, Andreas,
Wuschitz, Albert
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]
Use of multisensory environments in the home for people with dementia
The purpose of this pilot study was to explore the feasibility and effectiveness of using multisensory environments (MSE) in the home of people with dementia. A qualitative research design was used, which included semi-structured interviews and self-rated caregiver observation checklists. Field notes and audio recorded interviews were transcribed for data analysis. Data were reduced and […]